Abstract
Introduction
The occurrence of anti-CRPM5/CV2 antibodies is usually associated with paraneoplastic encephalomyelitis and with chorea as a possible feature, although typically being a multifocal syndrome [1] . On the other hand, paraneoplastic choreoathetosis (PNCA) is defined as a more or less isolated movement disorder as a remote effect of a cancer on the nervous system [1] . In PNCA, the most frequent neoplastic finding is small cell lung carcinoma (SCLC) [1] . We report such a rare case with papilledema as the only additional symptom.
Case Report
A 71-year-old woman presented to a general practitioner with a 5-day history of progressively decreasing left-sided vision. The sequelae of a prior surgery for a right-sided acoustic neuroma had left her with blindness on her right eye, right-sided hearing loss and peripheral facial palsy. She was a smoker with a history of 60 pack-years, and did not use medication daily. No family disposition could be obtained, since the patient was adopted. Over the previous 6 months, there had been an unintended weight loss of 10 kg. An ophthalmological examination revealed ischemic papillary stasis, which was treated with prednisone 80 mg/day. Furthermore, there was a sudden onset of involuntary movements of the upper and lower limbs. She was admitted to a hospital 7 days later. On neurological examination, she was alert and orientated. In addition to the already known features related to the treatment of an acoustic neuroma, there was universal choreoathetosis. The initial workup, including brain MRI (with T1, T2 and FLAIR sequences), and routine chest X-ray were all unremarkable. A whole-body PET scan did not reveal signs of primary or metastatic tumors. Further examinations with EEG and bronchoscopy were unremarkable. The following analyses of serum and cerebrospinal fluid were normal: ANA, ANCA, anti-Hu, anti-Yo, Riantibody, amphiphysin-1 antibody and anti-Zic4. However, anti-CRMP5 (alias anti-CV2, method: line-blot from Euroimmun, Lübeck, Germany) was strongly positive in both mediaalso indicating an occult cancer. She was then treated with immunoglobulin, which improved the choreiform movements. Unfortunately, over the following months, there was increasing weight loss, and the general condition worsened as well. Six months after the onset, a repeated PET scan showed foci suspicious of malignancy in the mediastinal lymph nodes and the right lung hilum. In May 2007, subsequent bronchoscopic biopsy revealed an SCLC. In spite of chemotherapy, repeated lung CT scans showed further progression, and the PNCA did not improve. As a palliative treatment for the SCLC, radiotherapy (10 Gy) was then given. She died 14 months after the onset of the symptoms, and her death was attributed to the SCLC complicated with infection.
Discussion
PNCA is an extremely rare disorder [1] . Most likely, it is caused by a damage of the nervous tissue by the remote effects of onconeuronal autoimmune factors including autoantibodies [1] . Associated with autoantibodies against intracellular epitopes, such a disorder is likely to be T cell mediated. It is provoked by cancer located outside the central nervous system and most frequently SCLC. However, based on the underlying pathogenesis, paraneoplastic disorders of the central nervous system can be divided into two categories: group 1 with antibodies against intracellular antigens (e.g. Hu and CRMP5/CV2) and group 2 with antibodies binding to superficial cell membrane structures (e.g. receptors and channels).
The occurrence of papilledema is explicable in terms of ischemic papillary stasis due to inflammation. Choreiform movements in the paraneoplastic syndrome have been reported in case reports of patients with different types of cancer, SCLC being the most frequently reported (table 1) . Common for nearly all reported cases of PNCA due to SCLC is the presence of CRPM5/CV2 antibodies (table 1) . Additionally, in patients with paraneoplastic chorea, the expected brain MRI finding is reduced signal intensity from the basal ganglia on the T1-weighted and increased intensity on the T2-weighted MRI scans. In the current case, however, such abnormalities were not observed. However, in half of the reported cases of PNCA, the MRI did not show changes in the basal ganglia (table 1) . Thus, in patients who present with new-onset and rapidly developing movement disorders and no pathological findings by routine biochemistry or brain MRI, a paraneoplastic origin should be considered. Moreover, paraneoplastic symptoms may occur months before the neoplastic disorder becomes detectable. An adequate diagnosis is a primary task for a neurologist, although a prompt and intensive workup may include an interdisciplinary team (e.g. ophthalmologists, radiologists, pulmonologists and oncologists). The outcome and prognosis depend on an early establishment of the diagnosis and a prompt start of therapy.
Movement disorders, including chorea, are common in the elderly. In view of the extreme scarcity of reported PNCA in contrast to a much more common occurrence of anti-CRMP5/CV2, PNCA may be underdiagnosed.
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